Find out how this UCSF faculty member started a company and raised venture capital. Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four leading-edge neuroscientists and stem cell pioneers at The University of California, San Francisco. Neurona is focused on the discovery and development of cell-based therapies to treat intractable neurological disease.
Dr. Cory Nicholas is Chief Scientific Officer at Neurona Therapeutics. Prior to launching Neurona, Dr. Nicholas was a faculty member in the Department of Neurology at the University of California, San Francisco where his research program was focused on elucidating the ontogeny of human cortical interneurons. Using embryonic brain development as a blueprint, Dr. Nicholas pioneered methods to derive interneuron precursors from human pluripotent stem cells and developed transplantation cell-based therapies for multiple animal models of neurological disease. He maintains an adjunct faculty appointment at the University. Dr. Nicholas’s post-doctoral studies were conducted at UCSF. His pre-doctoral work at both UCSF and Stanford University investigated germ cell development from both primordial germline and pluripotent stem cells. He received his Bachelor’s degree from the University of California, Berkeley. Prior to his interest in stem cell and developmental biology, Dr. Nicholas was a member of the discovery research team at Sugen, Inc.